Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

An undifferentiated carcinoma at Klatskin-position with long-term complete remission after chemotherapy.

Köhler BC, Goeppert B, Waldburger N, Schlamp K, Sauer P, Jäger D, Weiss KH, Macher-Göppinger S, Schulze-Bergkamen H, Schirmacher P, Springfeld C.

Oncotarget. 2018 Apr 24;9(31):22230-22235. doi: 10.18632/oncotarget.25125. eCollection 2018 Apr 24.

2.

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.

Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, Tessari A, Baumeister H, Danielczyk A, Dietrich B, Goletz S, Zurlo A, Salzberg M, Sessa C, Gianni L.

ESMO Open. 2018 Feb 1;3(2):e000303. doi: 10.1136/esmoopen-2017-000303. eCollection 2018.

3.

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.

Vogel A, Kasper S, Bitzer M, Block A, Sinn M, Schulze-Bergkamen H, Moehler M, Pfarr N, Endris V, Goeppert B, Merx K, Schnoy E, Siveke JT, Michl P, Waldschmidt D, Kuhlmann J, Geissler M, Kahl C, Evenkamp R, Schmidt T, Kuhlmann A, Weichert W, Kubicka S.

Eur J Cancer. 2018 Mar;92:11-19. doi: 10.1016/j.ejca.2017.12.028. Epub 2018 Feb 3.

PMID:
29413685
4.

Liver cancers with stem/progenitor-cell features - a rare chemotherapy-sensitive malignancy.

Köhler BC, Waldburger N, Schlamp K, Jäger D, Weiss KH, Schulze-Bergkamen H, Schirmacher P, Springfeld C.

Oncotarget. 2017 Jun 5;8(35):59991-59998. doi: 10.18632/oncotarget.19000. eCollection 2017 Aug 29.

5.

A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development.

Boege Y, Malehmir M, Healy ME, Bettermann K, Lorentzen A, Vucur M, Ahuja AK, Böhm F, Mertens JC, Shimizu Y, Frick L, Remouchamps C, Mutreja K, Kähne T, Sundaravinayagam D, Wolf MJ, Rehrauer H, Koppe C, Speicher T, Padrissa-Altés S, Maire R, Schattenberg JM, Jeong JS, Liu L, Zwirner S, Boger R, Hüser N, Davis RJ, Müllhaupt B, Moch H, Schulze-Bergkamen H, Clavien PA, Werner S, Borsig L, Luther SA, Jost PJ, Weinlich R, Unger K, Behrens A, Hillert L, Dillon C, Di Virgilio M, Wallach D, Dejardin E, Zender L, Naumann M, Walczak H, Green DR, Lopes M, Lavrik I, Luedde T, Heikenwalder M, Weber A.

Cancer Cell. 2017 Sep 11;32(3):342-359.e10. doi: 10.1016/j.ccell.2017.08.010.

6.

Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation.

Steinmetz C, Kashyap A, Zhivkova N, Alizor H, Ernst I, Gottfried-Brand D, Janssen H, Teufel A, Schulze-Bergkamen H, Lotz J, Kuball J, Theobald M, Heise M, Lang H, Galle PR, Strand D, Strand S.

Hepatology. 2017 Jun;65(6):2074-2089. doi: 10.1002/hep.29072. Epub 2017 Apr 28.

PMID:
28108987
7.

Possible Mechanisms of Ethanol-Mediated Colorectal Carcinogenesis: The Role of Cytochrome P4502E1, Etheno-DNA Adducts, and the Anti-Apoptotic Protein Mcl-1.

Koehler BC, Arslic-Schmitt T, Peccerella T, Scherr AL, Schulze-Bergkamen H, Bruckner T, Gdynia G, Jäger D, Mueller S, Bartsch H, Seitz HK.

Alcohol Clin Exp Res. 2016 Oct;40(10):2094-2101. doi: 10.1111/acer.13180. Epub 2016 Sep 1.

PMID:
27581253
8.

Bcl-xL is an oncogenic driver in colorectal cancer.

Scherr AL, Gdynia G, Salou M, Radhakrishnan P, Duglova K, Heller A, Keim S, Kautz N, Jassowicz A, Elssner C, He YW, Jaeger D, Heikenwalder M, Schneider M, Weber A, Roth W, Schulze-Bergkamen H, Koehler BC.

Cell Death Dis. 2016 Aug 18;7(8):e2342. doi: 10.1038/cddis.2016.233.

9.

Prolyl Hydroxylase 3 Attenuates MCL-1-Mediated ATP Production to Suppress the Metastatic Potential of Colorectal Cancer Cells.

Radhakrishnan P, Ruh N, Harnoss JM, Kiss J, Mollenhauer M, Scherr AL, Platzer LK, Schmidt T, Podar K, Opferman JT, Weitz J, Schulze-Bergkamen H, Koehler BC, Ulrich A, Schneider M.

Cancer Res. 2016 Apr 15;76(8):2219-30. doi: 10.1158/0008-5472.CAN-15-1474. Epub 2016 Feb 26.

10.

Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.

Bashari MH, Fan F, Vallet S, Sattler M, Arn M, Luckner-Minden C, Schulze-Bergkamen H, Zörnig I, Marme F, Schneeweiss A, Cardone MH, Opferman JT, Jäger D, Podar K.

Breast Cancer Res. 2016 Feb 26;18(1):26. doi: 10.1186/s13058-016-0686-4.

11.

Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach.

Flanagan L, Meyer M, Fay J, Curry S, Bacon O, Duessmann H, John K, Boland KC, McNamara DA, Kay EW, Bantel H, Schulze-Bergkamen H, Prehn JH.

Cell Death Dis. 2016 Feb 4;7:e2087. doi: 10.1038/cddis.2016.7.

12.

Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling.

Koehler BC, Jassowicz A, Scherr AL, Lorenz S, Radhakrishnan P, Kautz N, Elssner C, Weiss J, Jaeger D, Schneider M, Schulze-Bergkamen H.

BMC Cancer. 2015 Nov 19;15:919. doi: 10.1186/s12885-015-1929-y.

13.

CYLD deletion triggers nuclear factor-κB-signaling and increases cell death resistance in murine hepatocytes.

Urbanik T, Koehler BC, Wolpert L, Elßner C, Scherr AL, Longerich T, Kautz N, Welte S, Hövelmeyer N, Jäger D, Waisman A, Schulze-Bergkamen H.

World J Gastroenterol. 2014 Dec 7;20(45):17049-64. doi: 10.3748/wjg.v20.i45.17049.

14.

Hepatobiliary malignancies in Wilson disease.

Pfeiffenberger J, Mogler C, Gotthardt DN, Schulze-Bergkamen H, Litwin T, Reuner U, Hefter H, Huster D, Schemmer P, Członkowska A, Schirmacher P, Stremmel W, Cassiman D, Weiss KH.

Liver Int. 2015 May;35(5):1615-22. doi: 10.1111/liv.12727. Epub 2014 Nov 23.

PMID:
25369181
15.

Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma.

Welte S, Urbanik T, Elßner C, Kautz N, Koehler BC, Waldburger N, Bermejo JL, Pinna F, Weiss KH, Schemmer P, Jaeger D, Longerich T, Breuhahn K, Schulze-Bergkamen H.

PLoS One. 2014 Oct 16;9(10):e110591. doi: 10.1371/journal.pone.0110591. eCollection 2014.

16.

Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients.

Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Düber C, Lang H, Otto G, Wörns MA, Galle PR.

Liver Int. 2015 Feb;35(2):591-600. doi: 10.1111/liv.12696. Epub 2014 Oct 31.

PMID:
25290314
17.

Unresectable isolated hepatic metastases from solid pseudopapillary neoplasm of the pancreas: a case report of chemosaturation with high-dose melphalan.

Hofmann H, von Haken R, Werner J, Kortes N, Bergmann F, Schemmer P, Jäger D, Radeleff B, Schulze-Bergkamen H.

Pancreatology. 2014 Nov-Dec;14(6):546-9. doi: 10.1016/j.pan.2014.08.006. Epub 2014 Sep 16.

PMID:
25280592
18.

Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.

Koehler BC, Scherr AL, Lorenz S, Elssner C, Kautz N, Welte S, Jaeger D, Urbanik T, Schulze-Bergkamen H.

PLoS One. 2014 Sep 5;9(9):e106571. doi: 10.1371/journal.pone.0106571. eCollection 2014.

19.

Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction.

Kuehnle MC, Attig S, Britten CM, Schulze-Bergkamen H, Lordick F, von Wichert G, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Türeci O.

Cancer Immunol Immunother. 2014 Dec;63(12):1273-84. doi: 10.1007/s00262-014-1596-x. Epub 2014 Aug 28.

PMID:
25164876
20.

Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.

Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Wörns MA, Galle PR, Schulze-Bergkamen H.

J Clin Gastroenterol. 2015 May-Jun;49(5):438-47. doi: 10.1097/MCG.0000000000000176.

PMID:
25014239
21.

Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.

Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jäger D, Büchler MW, Weitz J, Koch M.

BMC Cancer. 2014 Mar 11;14:174. doi: 10.1186/1471-2407-14-174.

22.

Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.

Koehler BC, Jäger D, Schulze-Bergkamen H.

World J Gastroenterol. 2014 Feb 28;20(8):1923-34. doi: 10.3748/wjg.v20.i8.1923. Review.

23.

[Diagnosis of and therapy for hepatocellular carcinoma].

Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Düx M, Farkas S, Folprecht G, Galle P, Geißler M, Gerken G, Habermehl D, Helmberger T, Herfarth K, Hoffmann RT, Holtmann M, Huppert P, Jakobs T, Keller M, Klempnauer J, Kolligs F, Körber J, Lang H, Lehner F, Lordick F, Lubienski A, Manns MP, Mahnken A, Möhler M, Mönch C, Neuhaus P, Niederau C, Ocker M, Otto G, Pereira P, Pott G, Riemer J, Ringe K, Ritterbusch U, Rummeny E, Schirmacher P, Schlitt HJ, Schlottmann K, Schmitz V, Schuler A, Schulze-Bergkamen H, von Schweinitz D, Seehofer D, Sitter H, Straßburg CP, Stroszczynski C, Strobel D, Tannapfel A, Trojan J, van Thiel I, Vogel A, Wacker F, Wedemeyer H, Wege H, Weinmann A, Wittekind C, Wörmann B, Zech CJ.

Z Gastroenterol. 2013 Nov;51(11):1269-326. doi: 10.1055/s-0033-1355841. Epub 2013 Nov 15. German.

24.

Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.

Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opferman JT, Sattler M, Anderson KC, Jäger D, Podar K.

Cancer Lett. 2014 Feb 28;343(2):286-94. doi: 10.1016/j.canlet.2013.09.042. Epub 2013 Oct 8.

PMID:
24120758
25.

Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro.

Koehler BC, Scherr AL, Lorenz S, Urbanik T, Kautz N, Elssner C, Welte S, Bermejo JL, Jäger D, Schulze-Bergkamen H.

PLoS One. 2013 Oct 3;8(10):e76446. doi: 10.1371/journal.pone.0076446. eCollection 2013.

26.

Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.

Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, König J, Hoppe-Lotichius M, Hansen T, Pitton MB, Düber C, Otto G, Schuchmann M, Galle PR, Wörns MA.

J Clin Gastroenterol. 2014 Mar;48(3):279-89. doi: 10.1097/MCG.0b013e3182a8a793.

PMID:
24045276
27.

A reliable risk score for stage IV esophagogastric cancer.

Blank S, Lordick F, Dobritz M, Grenacher L, Burian M, Langer R, Roth W, Schaible A, Becker K, Bläker H, Sisic L, Stange A, Compani P, Schulze-Bergkamen H, Jäger D, Büchler M, Siewert JR, Ott K.

Eur J Surg Oncol. 2013 Aug;39(8):823-30. doi: 10.1016/j.ejso.2013.01.005. Epub 2013 Jan 31.

PMID:
23375470
28.

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.

Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.

Dig Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21.

PMID:
23182599
29.

Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.

Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hövelmeyer N, Hahn M, Schuchmann M, Jäger D, Waisman A, Wörns MA, Schulze-Bergkamen H.

J Hepatol. 2012 Nov;57(5):995-1003. doi: 10.1016/j.jhep.2012.06.017. Epub 2012 Jun 21.

PMID:
22728872
30.

Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo.

Schattenberg JM, Zimmermann T, Wörns M, Sprinzl MF, Kreft A, Kohl T, Nagel M, Siebler J, Schulze Bergkamen H, He YW, Galle PR, Schuchmann M.

J Hepatol. 2011 Dec;55(6):1272-80. doi: 10.1016/j.jhep.2011.03.008. Epub 2011 Apr 15.

PMID:
21703207
31.

Glycine and taurine equally prevent fatty livers from Kupffer cell-dependent injury: an in vivo microscopy study.

Bruns H, Watanpour I, Gebhard MM, Flechtenmacher C, Galli U, Schulze-Bergkamen H, Zorn M, Büchler MW, Schemmer P.

Microcirculation. 2011 Apr;18(3):205-13. doi: 10.1111/j.1549-8719.2010.00078.x.

PMID:
21175929
32.

Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.

Urbanik T, Köhler BC, Boger RJ, Wörns MA, Heeger S, Otto G, Hövelmeyer N, Galle PR, Schuchmann M, Waisman A, Schulze-Bergkamen H.

Int J Oncol. 2011 Jan;38(1):121-31.

PMID:
21109933
33.

Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice.

Weber A, Boger R, Vick B, Urbanik T, Haybaeck J, Zoller S, Teufel A, Krammer PH, Opferman JT, Galle PR, Schuchmann M, Heikenwalder M, Schulze-Bergkamen H.

Hepatology. 2010 Apr;51(4):1226-36. doi: 10.1002/hep.23479.

34.

TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.

Koehler BC, Urbanik T, Vick B, Boger RJ, Heeger S, Galle PR, Schuchmann M, Schulze-Bergkamen H.

World J Gastroenterol. 2009 Dec 21;15(47):5924-35.

35.

Novel ways to sensitise gastrointestinal cancer to apoptosis.

Schulze-Bergkamen H, Weinmann A, Moehler M, Siebler J, Galle PR.

Gut. 2009 Jul;58(7):1010-24. doi: 10.1136/gut.2008.164350. Review.

PMID:
19520891
36.

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.

J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6.

PMID:
19247201
37.

IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53.

Herzer K, Hofmann TG, Teufel A, Schimanski CC, Moehler M, Kanzler S, Schulze-Bergkamen H, Galle PR.

Cancer Res. 2009 Feb 1;69(3):855-62. doi: 10.1158/0008-5472.CAN-08-2831. Epub 2009 Jan 13.

38.

Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes.

Vick B, Weber A, Urbanik T, Maass T, Teufel A, Krammer PH, Opferman JT, Schuchmann M, Galle PR, Schulze-Bergkamen H.

Hepatology. 2009 Feb;49(2):627-36. doi: 10.1002/hep.22664.

39.

Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.

Schulze-Bergkamen H, Ehrenberg R, Hickmann L, Vick B, Urbanik T, Schimanski CC, Berger MR, Schad A, Weber A, Heeger S, Galle PR, Moehler M.

World J Gastroenterol. 2008 Jun 28;14(24):3829-40.

40.

Genetics of hepatocellular carcinoma.

Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR.

World J Gastroenterol. 2007 Apr 28;13(16):2271-82. Review.

41.

In vitro generated human memory-like T cells are CD95 type II cells and resistant towards CD95-mediated apoptosis.

Fas SC, Baumann S, Krueger A, Frey CR, Schulze-Bergkamen H, Brenner D, Stumpf C, Kappes K, Krammer PH.

Eur J Immunol. 2006 Nov;36(11):2894-903.

42.

Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.

Schulze-Bergkamen H, Fleischer B, Schuchmann M, Weber A, Weinmann A, Krammer PH, Galle PR.

BMC Cancer. 2006 Oct 2;6:232.

43.

Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.

Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, Walczak H, Fleischer B, Trautwein C, Michalski C, Schulze-Bergkamen H, Friess H, Stremmel W, Krammer PH, Schirmacher P, Müller M.

Cancer Res. 2006 Jul 15;66(14):7059-66.

44.

Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Büchler P, Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H.

Clin Cancer Res. 2006 Apr 15;12(8):2640-6.

45.

The role of apoptosis versus oncotic necrosis in liver injury: facts or faith?

Schulze-Bergkamen H, Schuchmann M, Fleischer B, Galle PR.

J Hepatol. 2006 May;44(5):984-93. Epub 2006 Mar 2. Review. No abstract available.

PMID:
16554101
46.

Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.

Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, Teufel A, Wörns M, Fischer T, Strand S, Lohse AW, Galle PR.

Oncol Rep. 2006 Jan;15(1):227-30.

PMID:
16328060
47.

Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma.

Fleischer B, Schulze-Bergkamen H, Schuchmann M, Weber A, Biesterfeld S, Müller M, Krammer PH, Galle PR.

Int J Oncol. 2006 Jan;28(1):25-32.

PMID:
16327976
48.

TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma.

Müller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W, Melino G, Krammer PH.

Cell Death Differ. 2005 Dec;12(12):1564-77. Epub 2005 Sep 30.

49.

Quantitative acylcarnitine profiling in peripheral blood mononuclear cells using in vitro loading with palmitic and 2-oxoadipic acids: biochemical confirmation of fatty acid oxidation and organic acid disorders.

Schulze-Bergkamen A, Okun JG, Spiekerkötter U, Lindner M, Haas D, Kohlmüller D, Mayatepek E, Schulze-Bergkamen H, Greenberg CR, Zschocke J, Hoffmann GF, Kölker S.

Pediatr Res. 2005 Nov;58(5):873-80. Epub 2005 Sep 23.

PMID:
16183823
50.

Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cells.

Herzer K, Ganten TM, Schulze-Bergkamen H, Grosse-Wilde A, Koschny R, Krammer PH, Walczak H.

Hepatology. 2005 Jul;42(1):183-92.

PMID:
15962328

Supplemental Content

Loading ...
Support Center